Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Summit Therapeutics PLC (SMMT) had Return on Tangible Equity of -219.78% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-565.71M |
|
-- |
|
-- |
|
$568.44M |
|
$-568.44M |
|
$2.73M |
|
$-565.71M |
|
$-565.71M |
|
$-565.71M |
|
$-565.71M |
|
$-565.71M |
|
$-565.71M |
|
$-568.44M |
|
$-568.40M |
|
742.62M |
|
742.62M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$309.24M |
|
$0.69M |
|
$14.80M |
|
$324.04M |
|
$60.33M |
|
-- |
|
$4.27M |
|
$64.60M |
|
$259.44M |
|
$257.40M |
|
$259.44M |
|
742.81M |
|
| Cash Flow Statement Financials | |
$-127.91M |
|
$310.92M |
|
$9.90M |
|
$105.19M |
|
$298.19M |
|
$193.00M |
|
$489.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-128.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-218.05% |
|
|
Return on Tangible Equity |
-219.78% |
-174.58% |
|
-218.05% |
|
$0.35 |
|
$-0.17 |
|
$-0.17 |
|